C. Schmid
University of Augsburg
13 Papers
17 Citations
C. Schmid is an academic researcher from University of Augsburg. The author has contributed to research in topics: Transplantation & Acute leukemia. The author has an hindex of 2, co-authored 13 publications.
Chat about Author
Papers
Sustained cellular immunity in adults recovered from mild COVID-19.
Andreas Rank,Phillip Löhr,Reinhard Hoffmann,Alanna Ebigbo,Stefanie Grützner,C. Schmid,Rainer Claus +6 more
TL;DR: In this paper, the authors demonstrate by extensive lymphocyte profiling in 44 adults after mild COVID-19 that cellular immunity is not fundamentally altered in convalescent patients, except for increased activated CD8+ lymphocytes.
11
Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT).
Francis Ayuk,Martin Bornhäuser,Matthias Stelljes,Tatjana Zabelina,Eva-Maria Wagner,C. Schmid,Maximilian Christopeit,Martina Guellstorf,Nicolaus Kröger,Wolfgang Bethge +9 more
TL;DR: The PIRCHE model, if validated in an independent cohort, may allow selection of permissible HLA mismatches that enable improved transplant outcome and be associated with lower overall survival and survival outcome after allogeneic stem cell transplantation from single mismatched unrelated donors.
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Andreas Rank,Christophe Peczynski,M. Labopin,Matthias Stelljes,Célestine Simand,Grzegorz Helbig,Jürgen Finke,Stella Santarone,Johanna Tischer,Andrzej Lange,Martin Mistrik,Mohamed Houhou,C. Schmid,Arnon Nagler,Mohamad Mohty +14 more
- 01 May 2021
TL;DR: Results after a third alloSCT are poor, limiting this procedure to few, highly selected patients, and recurrent relapses of acute leukemia after alloS CT remain an unmet therapeutic need.
8
Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies
Ralf Huss,C. Schmid,Mael Manesse,Jeppe Thagaard,Bruno Maerkl +4 more
- 01 Jul 2021
TL;DR: The relevance to understand the entire tumor heterogeneity and its environment, the contextual relationship and spatial quantification of all immune and tumor cells along with the genetic background of the individual cancer through the application of multiplex in‐situ technologies and theApplication of machine learning tools are summarized.
5